NAGE

Niagen Bioscience, Inc

3.370

+0.090+2.74%

Pre Market: 3.260 -0.110 -3.26%05:21 07/21 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.310/3.280

TODAY RANGE3.255-3.375

VOL23

MARKET CAP268.40M

52 WEEK RANGE3.175-11.29

AVG VOL (3M)863.09K

% TURNOVER0.74%

TURNOVER0

P/E (TTM)15.47

% RANGE3.66%

EPS(TTM)0.2179

P/E(FORWARD)14.98

P/B3.252

BVPS1.036

DIVIDEND--

P/S2.076

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP189.86M

SHARES OUTSTANDING79.64M

NEXT EARNINGS08/04-08/10

FREE FLOAT56.34M

LOT SIZE1

EX-DATE04/13/2016

News

Press Releases

Financial Reports

Profile

PUBT·4d ago
Niagen Bioscience names Abhijit Kale senior director of global external research
Reuters·4d ago
NIAGEN BIOSCIENCE APPOINTS ABHIJIT KALE, PH.D., AS SENIOR DIRECTOR OF GLOBAL EXTERNAL RESEARCH
PUBT·07/13 13:19
Niagen Bioscience wins FDA rare pediatric disease designation for NB4168 in ataxia telangiectasia
Reuters·07/13 12:49
BUZZ-Niagen rises after U.S., EU rare disease designations for drug candidate
TipRanks·07/13 12:35
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168
Reuters·07/13 12:32
NIAGEN BIOSCIENCE RECEIVES EXCLUSIVE U.S. FDA RARE PEDIATRIC DISEASE (RPD) DESIGNATION AND EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION (OMPD) FOR NB4168 FOR THE TREATMENT OF ATAXIA TELANGIECTASIA (A-T)
Reuters·07/10 21:07
NIAGEN BIOSCIENCE - MAY OFFER AND SELL COMMON STOCK UP TO $50 MLN - SEC FILING
TipRanks·07/09 10:35
Niagen Bioscience: Buy Rating Reiterated as Pipeline Advances; 12-Month Price Target Unchanged at $11
TipRanks·07/08 12:40
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
TipRanks·07/06 19:10
Niagen Bioscience initiated with a Buy at Freedom Broker
TipRanks·07/01 10:30
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Niagen Bioscience (NAGE) and AC Immune SA (ACIU)
TipRanks·06/29 21:03
Niagen Bioscience Shareholders Back Board and Governance Measures
PUBT·06/29 20:31
Niagen Bioscience holds annual shareholder meeting, elects directors
TipRanks·06/29 10:25
Niagen Bioscience files $125M mixed securities shelf
Reuters·06/29 10:03
NIAGEN BIOSCIENCE - UP TO $50 MLN OF COMMON STOCK MAY BE SOLD UNDER SALES AGREEMENT DATED JUNE 26, 2026 - SEC FILING

Same Industry

Name/Symbol

Change%

Price

NAGE

REGN

GRDX

BNTX

UTHR

Vertex Pharmaceuticals Inc

VRTX

-0.08%

485.65

SIGA

Moderna

MRNA

-2.11%

61.82

CRL

MEDP

TLPH

ICLR

CBPO

IQV

MOLECULAR PARTNERS AG

MOLN

-4.88%

3.900

ARCT

GILD

PRAH

INCY

APVO

BSTC

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.